Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.805 -0.095 (-1.94%)
Streaming Delayed Price Updated: 3:44 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing... 
Via FinancialNewsMedia
News headline image
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders ↗
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
News headline image
Atai Life Launches Depression-Focused Firm ↗
Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. ... 
Via Benzinga
Where ATAI Life Sciences Stands With Analysts ↗
ATAI Life Sciences (NASDAQ:ATAI) has observed the followi... 
Via Benzinga
What 9 Analyst Ratings Have To Say About ATAI Life Sciences ↗
ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst rating... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery ↗
Photo by CDC on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its... 
Via Benzinga
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... 
Via FinancialNewsMedia
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
Via FinancialNewsMedia
Topics Law Enforcement
News headline image
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study ↗
The Week In Psychedelics: 
Via Benzinga
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
News headline image
Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out ↗
DemeRx IB, Inc., a company developing psychedelic ibogaine for the treatment of opioid use disorder, has begun a phase 1/2... 
Via Benzinga
News headline image
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
Via FinancialNewsMedia
News headline image
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine ↗
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsid... 
Via Benzinga
News headline image
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗
Last Week In Psychedelics: 
Via Benzinga
News headline image
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
News headline image
Psychedelic Drug Industry Report Card For 2021 ↗
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
News headline image
What 10 Analyst Ratings Have To Say About ATAI Life Sciences ↗
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT... 
Via Benzinga
News headline image
21 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021 ↗
Upgrades For Chatham Lodging Trust (NYSE: 
Via Benzinga
News headline image
Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M ↗
Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: 
Via Benzinga
News headline image
Earnings Scheduled For August 16, 2021 ↗
Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company ↗
Peter Thiel-backed Atai Life Sciences (NASDAQ: ATAI) has launched a new portfolio company, Revixia Life Sciences. Revixia Life's primary mission is to... 
Via Benzinga
News headline image
Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary ↗
Atai Life Sciences (NASDAQ:ATAI) has announced the launch ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.